Patenting monoclonal antibodies in India : evolving law and practice

By: Srivastava, Neha
Publisher: 2021ISBN: 9781911432463Subject(s): Patenting of life forms -- India | Pharmaceuticals -- India | Patents -- Law and Legislation -- IndiaGenre/Form: Book chapter Local URL: SNIPER Full Text In: IAM Innovation and Invention Yearbook 2021 2021, pp. 93-98
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)

SNIPER Book Chapter

As efforts continue to find an effective treatment and vaccine for covid-19, monoclonal antibodies have been at the forefront of research with reportedly more than 100 covid-19 antibody treatments at various stages of clinical trials - some designed solely to deal with secondary effects of SARS-CoV-2 (eg, inflammation), while others are designed to destroy the vims itself. Monoclonal antibodies have dominated biotechnology research in the past 25 years, and it is interesting to see how Indian patent law has responded to their protection -- legal framework -- naturally occurring? -- broad antibody claims -- sufficiency of disclosure -- demonstrating inventive merits -- overcoming Section 3(d) of the Patents Act

Creative Commons Attribution 4.0 International (CC BY 4.0)

Item type Current library Call number Status Date due Barcode Item holds
SNIPER IP Australia Library
SNIPER Articles
2022/00383 (Browse shelf (Opens below)) Available 200803108
Total holds: 0

There are no comments on this title.

to post a comment.

Hosted by Prosentient